Literature DB >> 16982768

Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis.

Emanuela Aleo1, Clare J Henderson, Alessandra Fontanini, Barbara Solazzo, Claudio Brancolini.   

Abstract

Identification of alternative pathways of caspase activation is an important step to develop new antitumor treatments. We report here the result of a screening with a small chemical library, the Developmental Therapeutics Program-National Cancer Institute "challenge set," on cells expressing mutated caspase-9. We have identified two molecules capable of activating an apoptosome-independent apoptotic pathway. These compounds, named F6 and G5, target the ubiquitin-proteasome system by inhibiting the ubiquitin isopeptidases. We have shown that F6 and G5 induce a rather unique apoptotic pathway, which includes a Bcl-2-dependent but apoptosome-independent mitochondrial pathway with up-regulation of the BH3-only protein Noxa, stabilization of the inhibitor of apoptosis antagonist Smac, but also the involvement of the death receptor pathway. Noxa plays an important role in the induction of mitochondrial fragmentation and caspase activation, whereas the death receptor pathway becomes critical in the absence of a functional apoptosome. This study suggests that screening of chemical libraries on cancer cells with defined mutations in apoptotic key elements can lead to the identification of compounds that are useful to characterize alternative pathways of caspase activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982768     DOI: 10.1158/0008-5472.CAN-06-0702

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation.

Authors:  Giovanni Benard; Albert Neutzner; Guihong Peng; Chunxin Wang; Ferenc Livak; Richard J Youle; Mariusz Karbowski
Journal:  EMBO J       Date:  2010-03-18       Impact factor: 11.598

2.  The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.

Authors:  Ivana Manini; Andrea Sgorbissa; Harish Potu; Andrea Tomasella; Claudio Brancolini
Journal:  Cancer Biol Ther       Date:  2013-09-19       Impact factor: 4.742

Review 3.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

4.  Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.

Authors:  Xin Wang; Pádraig D'Arcy; Thomas R Caulfield; Aneel Paulus; Kasyapa Chitta; Chitralekha Mohanty; Joachim Gullbo; Asher Chanan-Khan; Stig Linder
Journal:  Chem Biol Drug Des       Date:  2015-05-27       Impact factor: 2.817

Review 5.  Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.

Authors:  Mingjing He; Zhuan Zhou; George Wu; Qianming Chen; Yong Wan
Journal:  Pharmacol Ther       Date:  2017-03-06       Impact factor: 12.310

6.  Emerging therapies targeting the ubiquitin proteasome system in cancer.

Authors:  Nathaniel M Weathington; Rama K Mallampalli
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

7.  Isopeptidases in anticancer therapy: looking for inhibitors.

Authors:  Andrea Sgorbissa; Harish Potu; Claudio Brancolini
Journal:  Am J Transl Res       Date:  2010-05-10       Impact factor: 4.060

Review 8.  1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets.

Authors:  U Das; R K Sharma; J R Dimmock
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

9.  A receptor-interacting protein 1 (RIP1)-independent necrotic death under the control of protein phosphatase PP2A that involves the reorganization of actin cytoskeleton and the action of cofilin-1.

Authors:  Andrea Tomasella; Anne Blangy; Claudio Brancolini
Journal:  J Biol Chem       Date:  2014-08-05       Impact factor: 5.157

10.  Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.

Authors:  Igor Landais; Sanne Hiddingh; Matthew McCarroll; Chao Yang; Aiming Sun; Mitchell S Turker; James P Snyder; Maureen E Hoatlin
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.